1. Главная
  2. Ресурсы
  3. Библиотечный поиск
Interaction ofCardiovascularNonmodifiable RiskFactors,Comorbidities andComedications WithIschemia/ReperfusionInjury andCardioprotection by… Péter FerdinandyIoanna AndreadouGary F. Baxter2022 год

Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning
review

Полный текстСтраница публикацииПубликация в OpenAlex
Аннотация: Preconditioning, postconditioning, and remote conditioning of the myocardium enhance the ability of the heart to withstand a prolonged ischemia/reperfusion insult and the potential to provide novel therapeutic paradigms for cardioprotection. While many signaling pathways leading to endogenous cardioprotection have been elucidated in experimental studies over the past 30 years, no cardioprotective drug is on the market yet for that indication. One likely major reason for this failure to translate cardioprotection into patient benefit is the lack of rigorous and systematic preclinical evaluation of promising cardioprotective therapies prior to their clinical evaluation, since ischemic heart disease in humans is a complex disorder caused by or associated with cardiovascular risk factors and comorbidities. These risk factors and comorbidities induce fundamental alterations in cellular signaling cascades that affect the development of ischemia/reperfusion injury and responses to cardioprotective interventions. Moreover, some of the medications used to treat these comorbidities may impact on cardioprotection by again modifying cellular signaling pathways. The aim of this article is to review the recent evidence that cardiovascular risk factors as well as comorbidities and their medications may modify the response to cardioprotective interventions. We emphasize the critical need for taking into account the presence of cardiovascular risk factors as well as comorbidities and their concomitant medications when designing preclinical studies for the identification and validation of cardioprotective drug targets and clinical studies. This will hopefully maximize the success rate of developing rational approaches to effective cardioprotective therapies for the majority of patients with multiple comorbidities.

Significance Statement

Ischemic heart disease is a major cause of mortality; however, there are still no cardioprotective drugs on the market. Most studies on cardioprotection have been undertaken in animal models of ischemia/reperfusion in the absence of comorbidities; however, ischemic heart disease develops with other systemic disorders (e.g., hypertension, hyperlipidemia, diabetes, atherosclerosis). Here we focus on the preclinical and clinical evidence showing how these comorbidities and their routine medications affect ischemia/reperfusion injury and interfere with cardioprotective strategies.
Год издания: 2022
Авторы: Péter Ferdinandy, Ioanna Andreadou, Gary F. Baxter, Hans Erik Bøtker, Sean M. Davidson, Dobromir Dobrev, Bernard J. Gersh, Gerd Heusch, Sandrine Lecour, Marisol Ruiz‐Meana, Coert J. Zuurbier, Derek J. Hausenloy, Rainer Schulz
Издательство: American Society for Pharmacology and Experimental Therapeutics
Источник: Pharmacological Reviews
Ключевые слова: Cardiac Ischemia and Reperfusion, Anesthesia and Neurotoxicity Research, Cardiac Arrest and Resuscitation
Другие ссылки: Pharmacological Reviews (PDF)
Pharmacological Reviews (HTML)
UCL Discovery (University College London) (PDF)
UCL Discovery (University College London) (HTML)
UCL Discovery (University College London) (HTML)
PubMed Central (HTML)
ORCA Online Research @Cardiff (Cardiff University) (HTML)
PubMed (HTML)